These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23087429)

  • 1. Monitoring HPV vaccine impact: early results and ongoing challenges.
    Hariri S; Markowitz L
    J Infect Dis; 2012 Dec; 206(11):1633-5. PubMed ID: 23087429
    [No Abstract]   [Full Text] [Related]  

  • 2. Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in the United States--National Health And Nutrition Examination Survey, 2003-2006: opportunity to measure HPV vaccine impact?
    Dunne EF; Sternberg M; Markowitz LE; McQuillan G; Swan D; Patel S; Unger ER
    J Infect Dis; 2011 Aug; 204(4):562-5. PubMed ID: 21791658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic HPV vaccination for the prevention of cervical cancer.
    Hernandez BY
    Hawaii Med J; 2007 Jul; 66(7):190-1. PubMed ID: 17879858
    [No Abstract]   [Full Text] [Related]  

  • 5. [Human papillomavirus vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society. September 2008].
    Abarca V K; Valenzuela B MT; Vergara F R; Luchsinger F V; Muñoz M A; Jiménez de la Jara J; Ripoll M E; O'Ryan G M
    Rev Chilena Infectol; 2008 Dec; 25(6):428-34. PubMed ID: 19194605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries.
    Wong CA; Saraiya M; Hariri S; Eckert L; Howlett RI; Markowitz LE; Brotherton JM; Sinka K; Martinez-Montañez OG; Kjaer SK; Dunne EF
    Vaccine; 2011 Jan; 29(5):878-85. PubMed ID: 20971113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postlicensure monitoring of HPV vaccination programmes.
    Markowitz LE; Hariri S
    Lancet Infect Dis; 2014 Oct; 14(10):904-5. PubMed ID: 25107681
    [No Abstract]   [Full Text] [Related]  

  • 8. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.
    Herrero R
    J Infect Dis; 2009 Apr; 199(7):919-22. PubMed ID: 19236278
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of an "old-fashioned method" to assess the clinical and economic impact of a HPV vaccination program.
    Mennini FS; Capone A; Favato G
    Gynecol Oncol; 2011 Oct; 123(1):175-6; author reply 177-8. PubMed ID: 21605891
    [No Abstract]   [Full Text] [Related]  

  • 10. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
    J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of human papillomavirus seroepidemiology to inform vaccine policy.
    Schiffman M; Safaeian M; Wentzensen N
    Sex Transm Dis; 2009 Nov; 36(11):675-9. PubMed ID: 19773679
    [No Abstract]   [Full Text] [Related]  

  • 12. HPV vaccine gets a shot in the arm.
    Honey K
    J Clin Invest; 2006 Dec; 116(12):3087. PubMed ID: 17143319
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccinating against HPV: A Call to Action.
    Poh A
    Cancer Discov; 2016 Mar; 6(3):222-3. PubMed ID: 26842650
    [No Abstract]   [Full Text] [Related]  

  • 14. Human papillomavirus vaccine: widening the scope for cancer prevention.
    No JH; Kim MK; Jeon YT; Kim YB; Song YS
    Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do HPV vaccine genotypes agree with circulating HPV types?
    Tartaglia E; Iafusco D; Galderisi A; Mastrantonio P
    Lancet Infect Dis; 2011 Aug; 11(8):585-6. PubMed ID: 21798460
    [No Abstract]   [Full Text] [Related]  

  • 16. HPV vaccine: a cornerstone of female health.
    Temte JL
    Am Fam Physician; 2007 Jan; 75(1):28, 30. PubMed ID: 17225700
    [No Abstract]   [Full Text] [Related]  

  • 17. Post-licensure monitoring of HPV vaccine in the United States.
    Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
    Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conclusions about the quadrivalent human papillomavirus vaccine efficacy based on alternate dosing schedules and less than three dose immunogenicity is inappropriate.
    Harper DM
    J Infect Dis; 2014 Jul; 210(2):330-1. PubMed ID: 24501212
    [No Abstract]   [Full Text] [Related]  

  • 19. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.